Frontlight ResearchEarly access
Enrolling by invitationPhase 1
Long-term safety follow-up of people treated with ADP cell therapy for cancer
Tracks long-term safety of people who received ADP cell therapy for cancer.
Key facts
- Who runs it
- USWM CT, LLC
- Where
- London, Manchester, and Sutton, United KingdomSee the 3 sitesAlso in 7 other countries, 21 sites
- Trial code
- Registry title
- Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
- Status
- Enrolling by invitation
- Phase
- Phase 1
- People taking part
- 250 people, planned
- Started
- 9 Apr 2018
- Expected to end
- 1 Apr 2032
- Type of study
- Interventional
- Treatments tested
- ADP adoptive cell therapy
- Record updated
- 11 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who already received ADP adoptive cell therapy. It follows their long-term safety for up to 15 years after the last infusion.
- Sex
- All sexes can join.
- Earlier treatment
- People must have had at least one dose of ADP adoptive cell therapy. They must have finished or left an ADP-sponsored or supported study, or finished treatment through managed access to a GSK adoptive cell therapy.
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Participants who have received at least one dose of ADP adoptive cell therapy agent
- Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it
- Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy
- Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
- The investigator is responsible for review of medical history
- Capable of giving signed informed consent
Who cannot take part
- None
Where in United Kingdom
Also in 7 other countries, 21 sites
- University College London Hospitals NHS Foundation TrustLondon, United KingdomEnrolling by invitation
- ManchesterHospital not named in the registryEnrolling by invitation
- The Royal Marsden NHS Foundation TrustSutton, United KingdomEnrolling by invitation
About the trial
What the trial wants to find out
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
The group in the trial
- Participants receiving ADP adoptive cell therapyTreatment being tested
Treatment: ADP adoptive cell therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
- Plain-language title
- Long-term safety follow-up of people treated with ADP cell therapy for cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 11 August 2026